Theravance Biopharma (TBPH) Accumulated Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Accumulated Expenses data on file, last reported at $8.7 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $8.7 million, up 62.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (up 62.09% YoY), and the FY2025 annual result was $12.6 million, up 79.4% from the prior year.
• Accumulated Expenses retreated to $8.7 million in Q1 2026 per TBPH's latest filing, from $12.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.6 million in Q4 2025 and troughed at $4.0 million in Q2 2022.
• A 5-year average of $7.1 million and a median of $6.6 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses soared 727.77% in 2022, then slumped 37.53% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $10.3 million in 2022, then plunged by 37.53% to $6.4 million in 2023, then grew by 8.94% to $7.0 million in 2024, then soared by 79.4% to $12.6 million in 2025, then slumped by 30.67% to $8.7 million in 2026.
• Business Quant data shows TBPH's Accumulated Expenses at $8.7 million in Q1 2026, $12.6 million in Q4 2025, and $10.3 million in Q3 2025.